Genes influence how you respond to medications through two distinct routes: they can change how your body processes a drug, or they can change how the drug acts once it arrives. The first route is called pharmacokinetics—what the body does to the drug. The second is pharmacodynamics—what the drug does to the body. The blood thinner warfarin shows how both can operate at once, with variants in the metabolizing enzyme CYP2C9 and the drug target VKORC1 combining to shape the dose a patient actually needs.
Pharmacokinetics: How Your Body Processes Drugs
Before a drug can exert its effect, your body must absorb, distribute, metabolize, and eventually eliminate it. Pharmacokinetics is the study of that journey. Writing in Circulation in 2011, Dan M. Roden and colleagues at Vanderbilt University School of Medicine, with Heyo K. Kroemer of Ernst Moritz Arndt University, noted that many important examples in pharmacogenetics relate to variable drug uptake, metabolism, or elimination.
Why does metabolism matter so much? Enzymes—mostly in the liver—chemically transform drugs, often converting them into forms that are easier to excrete. The genes that encode these enzymes come in variant forms, and a variant enzyme may work faster, slower, or not at all. The practical consequence is a change in drug concentration: too little enzyme activity and a standard dose can build up to toxic levels; too much and the drug may be cleared before it can act.
Consider warfarin. The drug is administered as a racemate—a mixture of two mirror-image molecules—and most of its anticoagulant action is mediated by the more potent S-enantiomer, as Roden and colleagues describe. S-warfarin is bioinactivated primarily by CYP2C9, an enzyme encoded by the CYP2C9 gene. If a patient carries CYP2C9 variants that reduce the enzyme's activity, S-warfarin is broken down more slowly. The active drug lingers, and the same dose that is safe for one person can over-anticoagulate another.
This is the pharmacokinetic pathway in its clearest form: the gene affects the enzyme, the enzyme affects the drug's concentration, and the concentration determines the response. Nothing about the drug's target has changed—only how long the drug stays in the body.
Pharmacodynamics: How Drugs Affect Your Body
Pharmacodynamics works from the opposite direction. A drug produces its effect by interacting with specific molecular targets—receptors, enzymes, or other proteins. The Vanderbilt-led review identifies variation in drug target molecules, and in disease pathways, as the other major contributor to variable drug responses identified through physiologically-based candidate approaches.
Here the logic is different. The concentration of the drug at the target may be perfectly normal, but the target itself responds differently. A variant in the gene encoding the target can alter how strongly the drug binds, or how much of the target is produced. The result is a change in the drug's efficacy or potency: the same concentration produces a weaker or stronger effect than in someone with the standard version of the target.
Warfarin illustrates this pathway too. The pharmacologic target for the drug is encoded by VKORC1, the gene for vitamin K epoxide reductase complex 1, a protein important for maintaining active vitamin K—which is essential for blood clotting. Warfarin works by inhibiting this target. Variants in VKORC1 can affect how sensitive the target is to the drug, meaning two patients with identical warfarin levels in their blood can still experience different degrees of anticoagulation.
So the two pathways are genuinely distinct. Pharmacokinetic variation changes how much drug is present; pharmacodynamic variation changes what a given amount of drug does. Both, however, feed into the same final outcome: the patient's response.
Warfarin: A Case Study in Gene-Drug Interaction
Warfarin is the textbook case because both pathways converge on a single clinical question: what dose should this patient receive? On the pharmacokinetic side, CYP2C9 variants slow the metabolism of the potent S-enantiomer. On the pharmacodynamic side, VKORC1 variants change the sensitivity of the drug's target. Roden and colleagues also note that other drug-metabolizing pathways and enzymes influencing vitamin K metabolism, such as EPHX1 and GGCX, contribute to the broader response pathway.
Crucially, these effects are not alternatives—they combine. The review describes this as "combinatorial pharmacogenetics," noting that in some cases variants in multiple genes are implicated in a drug response. A patient who carries both a slow-metabolism CYP2C9 variant and a high-sensitivity VKORC1 variant faces a compounded effect: the drug persists longer and each unit of drug acts more strongly. That patient's optimal warfarin dose will be substantially lower than average. The distribution of CYP2C9 and VKORC1 variants also varies as a function of ancestry, the authors report, meaning population background matters when interpreting genetic results.
Understanding Genetic Influence on Drug Response
The framework below separates the two causal pathways and maps the warfarin example onto each, showing how they combine into a single clinical outcome.
| Pathway | Gene example | Effect on drug | Role in warfarin response |
|---|---|---|---|
| Pharmacokinetics (what the body does to the drug) | CYP2C9 | Alters drug concentration by changing uptake, metabolism, or elimination | Encodes the enzyme that primarily bioinactivates the potent S-enantiomer; variants change how fast warfarin is cleared |
| Pharmacodynamics (what the drug does to the body) | VKORC1 | Alters the drug's efficacy or potency by changing the target | Encodes vitamin K epoxide reductase complex 1, warfarin's pharmacologic target; variants change target sensitivity |
| Combined effect | CYP2C9 + VKORC1 | Multiple gene variants act together on one response | Both sets of variants jointly determine an individual's optimal warfarin dose |
Read the table as a diagnostic tool. When you encounter a gene-drug interaction, first ask: does the variant change the enzyme that moves the drug through the body, or the molecule the drug acts upon? CYP2C9 belongs to the first category; VKORC1 to the second. Warfarin dosing requires both, which is why it became a leading example of combinatorial pharmacogenetics rather than a single-gene story.
The Future of Personalized Prescribing
Healthcare providers can move towards a more predictive approach to prescribing by considering a patient's genetic profile. The traditional model is essentially trial-and-error: start at a standard dose, monitor the response, and adjust. The warfarin example shows why that model is imperfect—two patients receiving the same dose can have genuinely different biology. Understanding whether a variant acts on metabolism or on the drug's target gives clinicians a mechanistic reason for the dose difference, not just an observed one.
There are boundaries to keep in mind. This article explains fundamental mechanisms; it is not a guide for interpreting personal genetic test results, and it does not provide medical advice or recommend specific tests or treatments. Warfarin, CYP2C9, and VKORC1 are illustrative examples, not a complete list of known gene-drug interactions.
The measurable indicator of progress is increased adoption of pharmacogenomic testing and integration of genetic data into clinical decision support systems. As that adoption grows, the shift from reactive dose adjustment to genetically informed prescribing becomes something we can actually count—patient by patient, and gene by gene.
